Extension Study for Participants in Studies That Include Belzutifan (MK-6482-043/LITESPARK-043)

StatusRecruiting

PhasePhase 3

SponsorMerck Sharp & Dohme LLC

Started2026-03-23

View on ClinicalTrials.gov ↗

Trial flagged as At Risk

Primary completion moved at least 3 months later Jan 14, 2034 → Apr 22, 2034

See other at-risk trials from Merck (MSD)

Amendment history

2026-09-24

Primary completion pushed: 2034-01-14 → 2034-04-22

Completion pushed: 2034-01-14 → 2034-04-22

2026-09-01

Study Status, Contacts/Locations v20

Study sites54 entries, revised

~~Zakład Diagnostyki Laboratoryjnej,~~ Centrum Onkologii im. Prof. Franciszka Lukaszczyka ( Site 2000)

2026-08-27

Study Status, Contacts/Locations v19

Trial sites expanded: 51 → 54 locations

2026-08-20

Study Status, Contacts/Locations v18

Study sites49→51

2026-08-06

Study Status, Contacts/Locations v17

Study sites48→49

2026-07-31

Study Status, Contacts/Locations v16

Study sites49→48

2026-07-24

Study Status, Contacts/Locations v15

Trial sites expanded: 46 → 49 locations

2026-07-17

Study Status, Contacts/Locations v14

Study sites44→46

2026-07-08

Study Status, Conditions, Arms and Interventions, Contacts/Locations, References v13

Trial sites expanded: 27 → 44 locations

InterventionsBelzutifan (Drug), Cabozantinib (Drug), Everolimus (Drug), Lenvatinib (Drug), Nivolumab (Drug), Palbociclib (Drug)→Belzutifan (Drug), Cabozantinib (Drug), Lenvatinib (Drug), Nivolumab (Drug)

2026-06-18

Study Status, Contacts/Locations v12

Trial sites expanded: 24 → 27 locations

2026-06-11

Study Status, Contacts/Locations v11

Trial sites expanded: 20 → 24 locations

2026-06-04

Study Status, Contacts/Locations v10

Trial sites expanded: 15 → 20 locations

2026-05-27

Study Status, Contacts/Locations v9

Study sites13→15

2026-05-21

Study Status, Contacts/Locations v8

Study sites12→13

2026-05-14

Study Status, Contacts/Locations v7

Study sites11→12

2026-05-08

Study Status, Contacts/Locations v6

Study sites10→11

2026-04-30

Study Status, Contacts/Locations v5

Study sites9→10

2026-04-22

Study Identification, Study Status, Contacts/Locations v4

Study sites8→9

2026-04-15

Study Status, Contacts/Locations v3

Trial sites expanded: 4 → 8 locations

2026-03-27

Study Status, Contacts/Locations v2

Trial sites expanded: 1 → 4 locations

2026-03-17

Not Yet Recruiting→Recruiting Study Status, Contacts/Locations v1

Trial statusNot Yet Recruiting→Recruiting

Start date2026-03-11→2026-03-23

Study sites0→1

2026-02-05

Original filing

Merck (MSD)

401 trials monitored

See 24 trials at risk

Researchers are looking for new ways to treat advanced solid tumors and von Hippel-Lindau (VHL)-related tumors: * Advanced means the cancer has spread to other parts of the body (metastatic) or cannot be removed with surgery * Solid tumors are cancers mostly in body organs and tissues, not in the blood or other body liquids * VHL-related tumors are tumors caused by VHL disease. VHL disease is passed down from parents to children and people with VHL disease have a higher chance of getting certain types of cancer Researchers want to learn about the long-term effects of a trial medicine called belzutifan. Belzutifan, also called MK-6482, is designed to block a protein that helps tumors grow and survive. This is an extension trial, which means only people who were in certain other belzutifan trials (called parent trials) may be able to join. The goal of this trial is to learn how long people live after they start taking belzutifan.

Trial Details

NCT Number	NCT07405164
Lead Sponsor	Merck Sharp & Dohme LLC
Conditions	Von Hippel-Lindau Disease, Malignant Neoplasms
Enrollment	450 participants
Start Date	2026-03-23
Primary Completion	2034-04-22 (estimated)
Study Completion	2034-04-22 (estimated)
Updated on ClinicalTrials.gov	2026-09-23